National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

autologous anti-gp100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes
Human autologous peripheral blood lymphocytes (PBLs) transduced with a glycoprotein 100 (gp100) epitope-determined T cell receptor (TCR) gene, with potential antineoplastic activity. PBLs are isolated from a melanoma patient and pulsed with a viral vector encoding the TCR specific for amino acid residues154-162 of gp100 (KTWGQYWQV). After expansion ex vivo, the transduced autologous PBLs, expressing this specific TCR, are reintroduced into the patient and bind to melanoma cells expressing the gp100 protein, which may result in specific cytotoxic T-lymphocyte (CTL) killing of gp100-expressing melanoma cells. gp100 is a melanocyte lineage-specific antigen overexpressed in melanomas. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)




Previous:Aurora kinase inhibitor BI 811283, Aurora kinase inhibitor MLN8054, Aurora kinase inhibitor SNS-314, Aurora kinase/VEGFR2 inhibitor CYC116, autologous Ad-CD154-transduced CLL B cells
Next:autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes, autologous anti-PSMA gene-modified T-cells, autologous dendritic cell-adenovirus CCL21 vaccine, autologous dendritic cell-adenovirus p53 vaccine, autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov